News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily｜Tech Stocks Rise for Two Consecutive Days; Nvidia Q4 Revenue Soars 75%; Circle Surges 35% (February 26, 2026)2Bitcoin’s upcoming $10.5B options expiry may end bear market: Here’s how3Bitcoin, Ethereum and Solana rally as analysts flag pause in ‘10 a.m. dump’ after Jane Street lawsuit
Apollo Shares Tumble 2.4% as Epstein-Linked Legal Probes Escalate NYSE Volume 177th
101 finance·2026/02/26 23:15
Flutter's 2.75 Stock Surge Defies Q4 Revenue Miss and 179th-Ranked Trading Volume
101 finance·2026/02/26 23:15
RCL Rises 1.9% on Strong Earnings Buys and Strategic Moves Despite 176th Volume Rank
101 finance·2026/02/26 23:15
PayPal Acquisition Frenzy: How Savvy Investors Are Actually Responding
101 finance·2026/02/26 23:12
BitMine’s shares drop by 4.93% as fluctuations in Ethereum push it down to 148th place in trading volume
101 finance·2026/02/26 23:09
Moody's Surges 3.47% on Earnings and AI Momentum, Ranks 153th in $830M Volume
101 finance·2026/02/26 23:09
Newmont Shares Rise 2.1% Following Argentina Expansion, Marking 133rd Investment Amid 910M Shares Traded
101 finance·2026/02/26 23:03
Flash
23:17
From the new UK fiscal year, crypto ETNs cannot be included in mainstream ISA accounts.Starting from the new fiscal year on April 6, UK investors will not be able to add crypto ETNs to their “Stocks and Shares ISA” tax-free accounts. The UK tax authority, HM Revenue and Customs (HMRC), currently classifies crypto ETNs only as assets eligible for the “Innovative Finance ISA,” and at present, no platforms plan to support such products. Investors who already hold crypto ETNs do not need to sell them, and HMRC stated it will continue to assess whether to adjust its policy.
23:10
Due to the impact of data events, Coupang, Inc.'s growth and profitability trends are expected to remain relatively flat in the coming months.This situation may place certain constraints on the company's overall performance. Although Coupang, Inc. has demonstrated strong growth momentum in the past, recent data events may cause its business expansion and profitability to face short-term pressure. Market observers are closely monitoring related developments to assess their long-term impact.
23:08
Rhythm Pharmaceuticals Inc. (referred to as Rhythm Pharmaceuticals) recently disclosed that some of its shareholders plan to further sell up to 2.4 million shares of common stock.This stock sale plan is led by existing shareholders, aiming to achieve their personal asset allocation goals. The transaction is expected to provide additional liquidity to the market, while potentially having some impact on the existing equity structure. The company emphasizes that this stock sale is a personal financial arrangement by the shareholders and does not involve the issuance of new shares by Rhythm Pharmaceuticals, so it will not have a dilutive effect on the company's total capital.
News